# ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma

> **NCT02431403** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Pusan National University Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** ESHAP-Imatinib

## Key facts

- **NCT ID:** NCT02431403
- **Lead sponsor:** Pusan National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2020-02
- **Final completion:** —
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2015-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431403, "ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02431403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*